NCT05641922撤回不适用
Pilot Study to Assess the Safety and Effectiveness of the Use of BioTraceIO 360 for PSM and Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Effectiveness
研究概览
简要总结
Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures
Single-center prospective single-arm clinical investigation.
Sample size - 10 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Scheduled and indicated for standard-of-care liver tumor ablation for either hepatocellular carcinoma (HCC) or metastatic liver tumor(s) microwave (MW) energy.
- •Patient must have at least one prior CT or CECT scan (up to 6 months before enrollment).
- •Tumor must be visualized on at least one diagnostic imaging modality (MRI or contrast-enhanced CT).
- •Single tumor, or multiple tumors only if the distance between the ablated tumor and all other tumors allows for distinct separation between the necrotic zones.
- •Distance between the tumor and the edge of any previous necrotic zones allows for distinct separation between the necrotic zones.
- •At least 21 years of age.
- •Able and willing to give informed consent.
- •Additional inclusion criteria for subgroup:
- •Single ablation, using a single ablation needle, per tumor.
排除标准
- •Planned ablation includes adjunctive means other than MW energy (e.g., ethanol, hepatic artery embolization, etc.).
- •Planned ablation includes the use of more than two ablation needles, per tumor
- •Ablation area cannot be visualized and monitored continuously using ultrasound throughout the entire ablation procedure.
- •Pregnant or breastfeeding.
- •Patient judged unsuitable for study participation by the physician for any other reason.
- •Currently participating in another clinical trial of an unapproved investigational device or drug that has not concluded the follow-up period.
- •Unable or unwilling to give informed consent.
- •Additional exclusion criteria for subgroup:
- •Liver tumor that cannot be ablated with a single ablation needle, according to the investigator's clinical opinion.
- •Planned ablation includes repositioning and/or overlapping ablations using a single ablation needle.
结局指标
主要结局
Effectiveness
时间窗: 1 year
The percentage of patients for whom (1) probe(s) position suggestion provided by the BioTraceIO 360 device is in agreement with the planned probe(s) position, as determined by the physician without the use of the device, or (2) clinically feasible probe(s) positioning suggestion was provided by the BioTraceIO 360 device, in addition to the planned probe(s) position by the physician without the use of the device
Safety
时间窗: 1 year
Incidence and severity of device-related adverse
次要结局
- Assessment Module (1)(1 year)
- Planning Module(1 year)
- Monitoring Module(1 year)
研究者
相似试验
终止
不适用
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation ProceduresMetastatic Liver CancerHepatocellular CarcinomaNCT05582018Techsomed Medical Technologies LTD4
已完成
不适用
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation ProceduresCarcinoma, HepatocellularMetastatic Liver CancerNCT04970212Techsomed Medical Technologies LTD65
已完成
不适用
Light Therapy for Onychomycosis StudyOnychomycosis of ToenailNCT05139888ToeFX Inc.126
进行中（未招募）
不适用
A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinoma, non resectableMedDRA version: 9.1Level: LLTClassification code 10033600Term: Pancreatic adenocarcinoma non-resectableEUCTR2006-005104-14-DEniversitätsklinikum Schleswig-Holstein20
已完成
不适用
A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital HollowCorrection of Volume Loss in the Infraorbital Hollow AreaNCT03777917Merz North America, Inc.66